Evidence map›Paper›PMID 42606123›Full record

ReviewThe Journal of clinical investigation2026

The gut microbiome and allograft outcomes: implications for heart transplantation.

Ivan Ðuran, W H Wilson Tang, Petra Mamic

Abstract readReview
In one paragraph

Review in The Journal of clinical investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Ivan ÐuranUniversity of Zagreb School of Medicine, Zagreb, Croatia.
W H Wilson TangKaufman Center for Heart Failure Treatment and Recovery; Heart, Vascular and Thoracic Institute; and.
Petra MamicDivision of Cardiovascular Medicine, Department of Medicine.

Funding

The Role of the Bifidobacterium Gut Microbiome Guild in Pathophysiology of Chronic Heart Failure with Reduced Ejection FractionK08HL164881 · NHLBI · STANFORD UNIVERSITY · PI Petra Mamic · 2024 to 2026
$498k
NHLBI NIH HHS K08 HL164881
6 · The paper itself

Abstract

Heart transplantation remains the gold standard therapy for patients with end-stage heart failure. However, post-transplant complications are considerable. Emerging evidence implicates the gut microbiome as a modifiable determinant of post-heart transplant outcomes through its influence on host immunity, metabolism, and inflammation. This Review synthesizes current understanding of gut microbiome dysregulation following solid organ transplantation, with particular emphasis on heart transplantation, examining mechanistic links underpinning important complications including allograft rejection, infection, metabolic dysfunction, and cardiac allograft vasculopathy. We critically evaluate bidirectional interactions between the gut microbiome and immunosuppressive drugs, assess the potential for microbiome profiling to serve as a predictive biomarker for post-transplant complications, and examine microbiome-targeted interventions including dietary modification, prebiotics, probiotics, and fecal microbiota transplant. Finally, we propose a translational roadmap to integrate microbiome science into heart transplant care to optimize immunosuppression, predict complications, and improve long-term outcomes for heart transplant recipients.

Indexed as

Gastrointestinal MicrobiomeGraft RejectionHeart FailureHeart TransplantationAllograftsAnimalsFecal Microbiota TransplantationHumansImmunosuppressive AgentsImmunosuppressive Agents

Identifiers

PMID42606123
PMCPMC13476144

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.